Literature DB >> 15249713

Current and future trials of the EORTC brain tumor group.

M J van den Bent1, R Stupp, A A Brandes, D Lacombe.   

Abstract

The EORTC Brain Tumor Group (BTG) is dedicated to clinical research of neoplasms of the brain. In the past years the BTG has carried out phase II and phase III trials on glial tumors, brain metastases and primary CNS lymphomas. Future studies will investigate novel drugs in combination with chemo-radiotherapy in glioblastoma multiforme, radiotherapy in meningioma, and chemotherapy in medulloblastoma. The BTG will also start a new phase III trial on newly diagnosed low-grade glioma comparing radiotherapy to temozolomide. In all our trials translational research is getting more and more important, often this is one of the most important ways to get useful conclusions from clinical trials. The wide recognition of the importance of translational research for clinical trials and in particular with targeted therapies implies that this type of research will become a mandatory element in many of our future trials. Copyright 2004 S. Karger GmbH, Freiburg

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15249713     DOI: 10.1159/000077974

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  5 in total

1.  Medulloblastoma with soft-tissue and skeletal metastases in an adult: A case report.

Authors:  Dianzhong Geng; Xiaohua Song; Jing Liu; Zeshun Yu; Fangling Ning
Journal:  Oncol Lett       Date:  2015-08-11       Impact factor: 2.967

2.  Adding 11C-methionine PET to the EORTC prognostic factors in grade 2 gliomas.

Authors:  A Smits; E Westerberg; D Ribom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-21       Impact factor: 9.236

3.  Adult primitive neuroectodermal tumors: the prognostic value of supratentorial location.

Authors:  Rikesh Gandhi; Ranjith Babu; Thomas J Cummings; Cory Adamson
Journal:  J Neurooncol       Date:  2013-05-30       Impact factor: 4.130

4.  Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.

Authors:  Thomas-Toan Tran; Martin Uhl; Jing Ying Ma; Lisa Janssen; Venkataraman Sriram; Steffen Aulwurm; Irene Kerr; Andrew Lam; Heather K Webb; Ann M Kapoun; Darin E Kizer; Glenn McEnroe; Barry Hart; Jonathan Axon; Alison Murphy; Sarvajit Chakravarty; Sundeep Dugar; Andrew A Protter; Linda S Higgins; Wolfgang Wick; Michael Weller; Darren H Wong
Journal:  Neuro Oncol       Date:  2007-05-23       Impact factor: 12.300

5.  Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas.

Authors:  Nader Pouratian; Jaime Gasco; Jonathan H Sherman; Mark E Shaffrey; David Schiff
Journal:  J Neurooncol       Date:  2006-11-03       Impact factor: 4.506

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.